- Home
- MCTR vs IOBT Comparison
MCTR vs IOBT Comparison
Compare MCTR & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCTR
- IOBT
- Stock Information
- Founded
- MCTR 2014
- IOBT 2014
- Country
- MCTR Hong Kong
- IOBT Denmark
- Employees
- MCTR N/A
- IOBT N/A
- Industry
- MCTR
- IOBT Biotechnology: Pharmaceutical Preparations
- Sector
- MCTR
- IOBT Health Care
- Exchange
- MCTR NYSE
- IOBT Nasdaq
- Market Cap
- MCTR 87.5M
- IOBT 79.7M
- IPO Year
- MCTR 2025
- IOBT 2021
- Fundamental
- Price
- MCTR $3.67
- IOBT $1.29
- Analyst Decision
- MCTR
- IOBT Strong Buy
- Analyst Count
- MCTR 0
- IOBT 3
- Target Price
- MCTR N/A
- IOBT $9.33
- AVG Volume (30 Days)
- MCTR 4.3M
- IOBT 233.2K
- Earning Date
- MCTR 01-01-0001
- IOBT 08-12-2025
- Dividend Yield
- MCTR N/A
- IOBT N/A
- EPS Growth
- MCTR N/A
- IOBT N/A
- EPS
- MCTR 0.00
- IOBT N/A
- Revenue
- MCTR $4,453,234.00
- IOBT N/A
- Revenue This Year
- MCTR N/A
- IOBT N/A
- Revenue Next Year
- MCTR N/A
- IOBT N/A
- P/E Ratio
- MCTR $2,983.01
- IOBT N/A
- Revenue Growth
- MCTR N/A
- IOBT N/A
- 52 Week Low
- MCTR $3.52
- IOBT $0.66
- 52 Week High
- MCTR $54.91
- IOBT $1.73
- Technical
- Relative Strength Index (RSI)
- MCTR N/A
- IOBT 49.63
- Support Level
- MCTR N/A
- IOBT $1.26
- Resistance Level
- MCTR N/A
- IOBT $1.57
- Average True Range (ATR)
- MCTR 0.00
- IOBT 0.13
- MACD
- MCTR 0.00
- IOBT -0.04
- Stochastic Oscillator
- MCTR 0.00
- IOBT 19.46
About MCTR CTRL GROUP LTD
CTRL Group Ltd is an integrated marketing and advertising services provider in Hong Kong specializing in mobile games promotion for the local market. It provide services to mobile game developers, principally developers of mobile gaming applications or apps that gamers download from the developers' websites and applicable mobile operating systems, such as Apple Store or Android Google Play Store.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.